1.Abbasian, M. H., Abbasi, B., Ansarinejad, N., Motevalizadeh
Ardekani, A., Samizadeh, E., Gohari Moghaddam, K., & Hashemi,
M. R. (2018). Association of interleukin-1 gene polymorphism
with risk of gastric and colorectal cancers in an Iranian population.
Iranian Journal of Immunology, 15(4), 321-328.
2.Abbasian, M. H., Ansarinejad, N., Abbasi, B., Iravani, M.,
Ramim, T., Hamedi, F., & Ardekani, A. M. (2020). The Role
of Dihydropyrimidine Dehydrogenase and Thymidylate
Synthase Polymorphisms in Fluoropyrimidine-Based Cancer
Chemotherapy in an Iranian Population. Avicenna journal of
medical biotechnology, 12(3), 157.
3.Adjei, A. A. (2004). Pemetrexed (ALIMTA), a novel multitargeted
antineoplastic agent. Clinical Cancer Research, 10(12),
4276s-4280s.
4.Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A.,
& Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-
424.
5.Chen, C.-Y., Chang, Y.-L., Shih, J.-Y., Lin, J.-W., Chen, K.-
Y., Yang, C.-H., . . . Yang, P.-C. (2011). Thymidylate synthase
and dihydrofolate reductase expression in non-small cell lung
carcinoma: the association with treatment efficacy of pemetrexed.
Lung Cancer, 74(1), 132-138.
6.Chen, F., Wen, T., Lv, Q., & Liu, F. (2020). Associations between
Folate Metabolism Enzyme Polymorphisms and Lung Cancer: A
Meta-Analysis. Nutrition and Cancer, 72(7), 1211-1218.
7.Corrigan, A., Walker, J., Wickramasinghe, S., Hernandez,
M., Newhouse, S., Folarin, A., Marinaki, A. (2014).
Pharmacogenetics of pemetrexed combination therapy in lung
cancer: pathway analysis reveals novel toxicity associations. The
pharmacogenomics journal, 14(5), 411-417.
8.De Mattia, E., & Toffoli, G. (2009). C677T and A1298C MTHFR
polymorphisms, a challenge for antifolate and fluoropyrimidine-
based therapy personalisation. European Journal of Cancer, 45(8),
1333-1351.

9.Haerian, M. S., Haerian, B. S., Molanaei, S., Kosari, F., Sabeti, S.,
Bidari-Zerehpoosh, F., . . . Zali, M. R. (2016). MTHFR rs1801133
polymorphism and susceptibility to colorectal cancer in Iranian
population: evidence of a case–control study and meta-analysis.
Pharmacogenomics, 17(17), 1957-1965.
10.Hong, W., Wang, K., Zhang, Y.-p., Kou, J.-y., Hong, D., Su, D.,
. . . Wang, X.-j. (2013). Methylenetetrahydrofolate reductase
C677T polymorphism predicts response and time to progression
to gemcitabine-based chemotherapy for advanced non-small cell
lung cancer in a Chinese Han population. Journal of Zhejiang
University Science B, 14(3), 207-215.
11.Houshmand, M., Seresht-Ahmadi, M., & Alikarami, M. (2020).
Evaluation of the relationship between intronic polymorphism
TPO gene and risk of type 2 diabetes in Tehran population.
Personalized Medicine Journal, 4(16), 9-11.
12.Jiang, H., & Shen, Y. (2019). Methylene tetrahydrofolate
reductase (MTHFR) gene rs1801133 C> T polymorphisms and
response to 5-FU based chemotherapy in patients with colorectal
cancer: a meta-analysis. Pteridines, 30(1), 126-132.
13.Jung, M., Lee, C. H., Park, H. S., Lee, J. H., Kang, Y. A., Kim,
S. K., . . . Kim, J. H. (2013). Pharmacogenomic assessment of
outcomes of pemetrexed-treated patients with adenocarcinoma of
the lung. Yonsei Medical Journal, 54(4), 854-864.
14.Kim, Y.-I. (2009). Role of the MTHFR polymorphisms in cancer
risk modification and treatment.
15.Krawczyk, P., Kucharczyk, T., Kowalski, D. M., Powrózek, T.,
Ramlau, R., Kalinka-Warzocha, E., . . . Kałakucka, K. (2014).
Polymorphisms in TS, MTHFR and ERCC1 genes as predictive
markers in first-line platinum and pemetrexed therapy in NSCLC
patients. Journal of Cancer Research and Clinical Oncology,
140(12), 2047-2057.
16.Kucharczyk, T., Krawczyk, P., Powrózek, T., Kowalski, D. M.,
Ramlau, R., Kalinka-Warzocha, E., . . . Milanowski, J. (2016).
The effectiveness of pemetrexed monotherapy depending on
polymorphisms in TS and MTHFR genes as well as clinical
factors in advanced NSCLC patients. Pathology & Oncology
Research, 22(1), 49-56.
17.Lan, G., Lin, L., Chen, X., Chen, L., & Chen, X. (2017).
Correlation between methylenetetrahydrofolate reductase
(MTHFR) C677T polymorphisms and pemetrexed chemotherapy
efficacy/toxicity in non-squamous non-small cell lung cancer.
Medical science monitor: international medical journal of
experimental and clinical research, 23, 5683.
18.Liew, S.-C., & Gupta, E. D. (2015). Methylenetetrahydrofolate
reductase (MTHFR) C677T polymorphism: epidemiology,
metabolism and the associated diseases. European Journal of
Medical Genetics, 58(1), 1-10.
19.Luo, Y.-H., Luo, L., Wampfler, J. A., Wang, Y., Liu, D., Chen,
Y.-M., . . . Yang, P. (2019). 5-year overall survival in patients
with lung cancer eligible or ineligible for screening according
to US Preventive Services Task Force criteria: a prospective,
observational cohort study. The lancet oncology, 20(8), 1098-
1108.
20.Malsagova, K. A., Butkova, T. V., Kopylov, A. T., Izotov, A. A.,
Potoldykova, N. V., Enikeev, D. V., . . . Kaysheva, A. L. (2020).
Pharmacogenetic Testing: A Tool for Personalized Drug Therapy
Optimization. Pharmaceutics, 12(12), 1240.
21.Nishiyama, A., Katakami, N., Yoshioka, H., Iwasaku, M., Korogi,
Y., Hata, A., . . . Uchida, J. (2015). Retrospective efficacy and
safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-
mutation-negative patients with previously treated advanced non-
squamous non-small-cell lung cancer. Lung Cancer, 89(3), 301-
305.
22.Niyikiza, C., Baker, S. D., Seitz, D. E., Walling, J. M., Nelson,
K., Rusthoven, J. J., . . . Allen, R. H. (2002). Homocysteine and
Methylmalonic Acid: Markers to Predict and Avoid Toxicity from
Pemetrexed Therapy 1 Supported by Eli Lilly and Company. 1.
Molecular Cancer Therapeutics, 1(7), 545-552.
23.Shen, H., Zhu, M., & Wang, C. (2019). Precision oncology of lung
cancer: genetic and genomic differences in Chinese population.
NPJ precision oncology, 3(1), 1-8.
24.Tan, L.-M., Qiu, C.-F., Zhu, T., Jin, Y.-X., Li, X., Yin, J.-Y., . .
. Liu, Z.-Q. (2017). Genetic polymorphisms and platinum-based
chemotherapy treatment outcomes in patients with non-small cell
lung cancer: a genetic epidemiology study based meta-analysis.
Scientific Reports, 7(1), 1-19.
25.Tiseo, M., Giovannetti, E., Tibaldi, C., Camerini, A., Di Costanzo,
F., Barbieri, F., . . . Smit, E. F. (2012). Pharmacogenetic study
of patients with advanced non-small cell lung cancer (NSCLC)
treated with second-line pemetrexed or pemetrexed–carboplatin.
Lung Cancer, 78(1), 92-99.
26.Vázquez, C., Orlova, M., Verzura, M. A., Minatta, J. N., Scibona,
P., Jáuregui, E. G., . . . Belloso, W. H. (2019). Severe toxicity in
adult patients with lung cancer under treatment with pemetrexed:
a prospective cohort study. Journal of Chemotherapy, 31(2), 95-
104.
27.Zhang, X., Zhang, D., Huang, L., Li, G., Chen, L., Ma, J., . . .
Zhou, C. (2019). Discovery of novel biomarkers of therapeutic
responses in Han Chinese pemetrexed-based treated advanced
NSCLC patients. Frontiers in Pharmacology, 10, 944.
28.Zhong, L., Fu, Q., Zhou, S., Chen, L., & Peng, Q. (2018).
Relevance of MTHFR polymorphisms with response to
fluoropyrimidine-based chemotherapy in oesophagogastric
cancer: a meta-analysis. BMJ open, 8(5), e020767